Search

Previous data suggested that allo-SCT might be an effective therapy in the setting of chemo-refractory/relapsed diseases because of the potent long-term immune-mediated tumor control. This retrospective study aimed to analyze the outcome of adult patients who received allo-SCT in a chemo-refractory/relapsed status. The series included 840 patients with active or progressive disease at the time of transplant. Median age was 50 years. With a median follow-up of 40 months, 3-year OS, disease-free survival (DFS), and non-relapse mortality rates were 29±2, 23±2, and 30±2%, respectively. At the last follow-up, 252 patients (30%) were still alive (of whom 201 were in CR (24%). In a Cox multivariate analysis, the use of a reduced-intensity conditioning (RIC) before allo-SCT and use of an HLA-identical sibling donor remained independently associated with a better OS (hazard ratio (HR)=0.82; 95% confidence interval (CI), 0.69-0.98, P=0.03; and HR=0.79; 95% CI, 0.66-0.93, P=0.006, respectively). Also, a diagnosis of myelodysplastic syndrome/myeloproliferative disorder, Hodgkin lymphoma and non-Hodgkin lymphoma compared with acute leukemia had a favorable impact on OS (HR=0.55; 95% CI, 0.45-0.68, P<0.0001; HR=0.49; 95% CI, 0.31-0.75, P=0.001; and HR=0.47; 95% CI, 0.35-0.63, P<0.0001, respectively). In conclusion, this study suggests that allo-SCT may be of benefit in some subgroups of patients with active or progressive hematological malignancies at the time of allo-SCT. [ABSTRACT FROM AUTHOR]

Provides information on allogeneic bone marrow transplantation in patients with follicular lymphoma. Graft-versus-lymphoma effect of the transplantation; Reason for the need to define indications and use of prospective protocols involving less toxic transplant procedure; Effect of myeloablative conditioning regimens on post-transplant morbidity and mortality.

A letter to the editor regarding the use of biosimilars of granulocyte-colony stimulating factor (G-CSF)-like filgrastim on lymphoma and myeloma patients who underwent peripheral blood stem cell transplant (PBSCT).

A letter to the editor is presented which discusses the relationship of etoposide, cytarabin, cisplatin and methylpredisolone (ESHAP) chemotherapy to lenalidomide causes complete isotopic remission in Hodgkin disease which relapses after an autologous stem cell transplantation.